Global Pharmaceutical Company Commits to a Dual-Site Deal with AGC Biologics Exceeding €0.5 Billion

COPENHAGEN, Denmark, Nov 4 (Bernama) -- AGC Biologics has expanded its existing long-term manufacturing agreement with a global pharmaceutical company, adding a second supply node at the CDMO’s Copenhagen facility. The expansion, which builds on the existing agreement anchored at AGC Biologics’ Yokohama site, grows the deal’s total value beyond €0.5 billion.

The expanded deal calls for multi-product drug substance manufacturing across six biologics programs at AGC Biologics’ Copenhagen site, encompassing process transfer, scale-up, validation, and commercial production. Products will launch and move across facilities with several dual regulatory submissions to optimize capacity, cost, and local manufacturing benefits, capturing levels of flexibility and supply chain robustness that could not be achieved with a single-site supply arrangement.